Pharmacologic Therapy for Periocular Infantile Hemangiomas: A Review of the Literature

REFERENCES

• Bruckner A L, Freiden I J. Hemangiomas of infancy. Journal of the American Academy of Dermatology 2003; 48(4)477–496
   PubMedGoogle Scholar
• Goldberg N S, Rosanova M A. Periorbital hemangiomas. Dermatology Clinic 1992; 10: 653–661
   PubMed Web of Science ®Google Scholar
• Schwartz S R, Blei F, Ceisler E, et al. Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit. Journal of AAPOS 2006; 10: 262–268
   PubMed Web of Science ®Google Scholar
• Haik B G, Karcioglu Z A, Gordon R A, et al. Capillary hemangioma (infantile periocular hemangioma). Survey of Ophthalmology 1994; 38: 399–426
   PubMed Web of Science ®Google Scholar
• Ritter R, Butschek R A, Friedlander M, et al. Pathogenesis of infantile hemangioma: New molecular and cellular insights. Expert Reviews in Molecular Medicine 2007; 9(32)1–19
   PubMedGoogle Scholar
• Hoepfel-Kreiner I. Histogenesis of hemangiomas—An ultrastructural study on capillary and cavernous hemangiomas of the skin. Pathology, Research and Practice 1980; 170: 70–90
   PubMedGoogle Scholar
• Kraling B M, Razon M J, Boon L M, et al. E-selectin is present in proliferating endothelial cells in human hemangiomas. The American Journal of Pathology 1996; 148(4)1181–1191
   PubMedGoogle Scholar
• Ritter M R, Dorrell M I, Edmonds J, et al. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proceedings of the National Academy of Sciences of the United States of America 2002; 99(11)7455–7460
   PubMedGoogle Scholar
• Tan S T, Velikovic M, Ruger B M, et al. Cellular and extracellular markers of hemangioma. Plastic and Reconstructive Surgery 2000; 106(3)529–538
   PubMed Web of Science ®Google Scholar
• Beilenberg D R, Bucana C D, Sanchez R, et al. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. International Journal of Oncology 1999; 14(3)401–408
   PubMedGoogle Scholar
• Takahashi K, Mulliken J B, Kozakewich H P, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. The Journal of Clinical Investigation 1994; 93(6)2357–2364
   PubMed Web of Science ®Google Scholar
• Chang J, Most D, Bresnick S, et al. Proliferative hemangiomas: Analysis of cytokine gene expression and angiogenesis. Plastic and Reconstructive Surgery 1999; 103(1)1–9
   PubMed Web of Science ®Google Scholar
• Choi K, Kenedy M, Kazarov A, et al. A common precursor for hematopoietic and endothelial cells. Development 1998; 125(4)725–732
   PubMedGoogle Scholar
• Ferrara N, Kerbel R S. Angiogenesis as a therapeutic target. Nature 2005; 438(7070)967–974
   PubMed Web of Science ®Google Scholar
• Zarem H A, Edgerton M T. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg 1967; 39: 76–83
   PubMed Web of Science ®Google Scholar
• Zweichfach B W, Shoor E, Black M M. The influence of adrenal cortex on behavior of terminal vascular bed. Ann N Y Acad Sci 1953; 56: 626–633
   PubMedGoogle Scholar
• Folkman J, Langer R, Linhardt R, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983; 221: 719–725
   PubMed Web of Science ®Google Scholar
• Sasaki G H, Pang C Y, Wittliff J L. Pathogenesis and treatment of infant skin strawberry hemangiomas: Clinical and in vitro studies of hormonal effects. Plast Reconstr Surg Mar, 1984; 73(3)359–370
   PubMedGoogle Scholar
• Hasan Q, Tan S T, Gush J, Peters S G, Davis P F. Steroid therapy of a proliferating hemangioma: Histochemical and molecular changes. Pediatrics 2000; 105: 117–121
   PubMed Web of Science ®Google Scholar
• Hasan Q, Tan S T, Gush J, Davis P F. Altered mitochondrial cytochrome b gene expression during the regression of hemangioma. Plastic and Reconstructive Surgery 2001; 108: 1471–1476
   PubMedGoogle Scholar
• Hasan Q, Tan S T, Xu B, Davis P F. Effects of five commonly used glucocorticoids on haemangioma in vitro. Clinical and Experimental Pharmacology and Physiology 2003; 30: 140–144
   PubMedGoogle Scholar
• Bennett M, Fleischer A, Chamlin S, Frieden I. Oral corticosteroid use is effective for cutaneous hemangiomas. Archives of Dermatology 2001; 137: 1208–1213
   PubMedGoogle Scholar
• Sadan N, Wolach B. Treatment of hemangiomas of infants with high doses of prednisone. Journal of Pediatrics 1996; 128: 141–146
   PubMed Web of Science ®Google Scholar
• Delesalle F, Staumont D, Houmany M A, et al. Pulse methylprednisolone therapy for threatening periocular haemangiomas of infancy. Acta Dermato Venereologica 2006; 86: 429–432
   PubMedGoogle Scholar
• Boon L M, MacDonald D M, Mulliken J B. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg Nov, 1999; 104(6)1616–1623
   PubMedGoogle Scholar
• George M E, Sharma V, Jacobson J, Simon S, Nopper A J. Adverse effects of systemic glucosteroid therapy in infants with hemangiomas. Arch Dermatol Aug, 2004; 140(8)963–969
   PubMedGoogle Scholar
• Coats D K, O'Neil J W, D'Elia V J, et al. Sub-Tenon's infusion of corticosteroids for treatment of orbital hemangiomas. Ophthalmology 2003; 110: 1255–1259
   PubMedGoogle Scholar
• Friling R, Axer-Siegel R, Ben-Amitai D, et al. Intralesional and sub-Tenon's infusion of corticosteroids for treatment of refractory periorbital and orbital capillary haemangioma. Eye, (in press)
   Google Scholar
• Kushner B J. Intralesional corticosteroid injection for infantile adnexal hemangioma. American Journal of Ophthalmology 1982; 93: 496–506
   PubMed Web of Science ®Google Scholar
• Morrell A J, Willshaw H E. Normalization of refractive error after steroid injection for adnexal haemangiomas. British Journal of Ophthalmology 1991; 75: 301–305
   PubMedGoogle Scholar
• Weiss A H, Kelly J P. Reappraisal of astigmatism induced by periocular capillary hemangioma and treatment with intralesional corticosteroid injection. Ophthalmology 2008; 115: 390–397
   PubMed Web of Science ®Google Scholar
• Egbert J E, Paul S, Engel W K, et al. High injection pressure during intralesional injection of corticosteroids into capillary hemangiomas. Archives of Ophthalmology 2001; 119: 677–683
   PubMedGoogle Scholar
• Shorr N, Seiff S R. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surgery 1986; 17: 229–231
   PubMedGoogle Scholar
• Ruttum M S, Abrams G W, Harris G J, Ellis M K. Bilateral retinal embolization associated with intralesional corticosteroid injection for capillary hemangioma of infancy. Journal of Pediatric Ophthalmology and Strabismus 1993; 30: 4–7
   PubMed Web of Science ®Google Scholar
• Egbert J E, Schwartz G S, Walsh A W. Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma. American Journal of Ophthalmology 1996; 121: 638–642
   PubMed Web of Science ®Google Scholar
• Droste P J, Ellis F D, Sondhi N, et al. Linear subcutaneous fat atrophy after corticosteroid injection of periocular hemangiomas. American Journal of Ophthalmology 1988; 105: 65–69
   PubMed Web of Science ®Google Scholar
• Dyment P G. Local atrophy following triamcinolone injection. Pediatrics 1970; 46: 136–137
   PubMed Web of Science ®Google Scholar
• Sutula F C, Glover A T. Eyelid necrosis following intralesional corticosteroid injection for capillary hemangioma. Ophthalmic Surg 1987; 18: 103–105
   PubMedGoogle Scholar
• Weiss A H. Adrenal suppression after corticosteroid injection of periocular hemangiomas. American Journal of Ophthalmology 1989; 107: 518–522
   PubMed Web of Science ®Google Scholar
• Ranchod T M, Frieden I J, Fredrick D R. Corticosteroid treatment of periorbital haemangioma of infancy: A review of the evidence. British Journal of Ophthalmology 2005; 89(9)1134–1138
   PubMedGoogle Scholar
• Elsas F J, Lewis A R. Topical treatment of periocular capillary hemangioma. Strabismus 1994; 31: 153–156
   Google Scholar
• Cruz O A, Zarnegar S R, Myers S E. Treatment of periocular capillary hemangioma with topical clobetasol propionate. Ophthalmology 1995; 102: 2012–2015
   PubMed Web of Science ®Google Scholar
• Garzon M C, Lucky A W, Hawrot A, et al. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. Journal of the American Academy of Dermatology 2005; 52: 281–286
   PubMed Web of Science ®Google Scholar
• Groopman J E, Gottlieb M S, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immune deficiency syndrome. Annals of Internal Medicine 1984; 100: 671–676
   PubMed Web of Science ®Google Scholar
• White C W, Sondheimer H M, Crouch E C, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320: 1197–1200
   PubMed Web of Science ®Google Scholar
• Orchard P J, Smith C M, 3rd, Woods W G, et al. Treatment of haemangioendotheliomas with alpha interferon. Lancet 1989; 2: 565–567
   PubMed Web of Science ®Google Scholar
• Ezekowitz R AB, Mulliken J B, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy [published erratum appears in N Engl J Med 1994;330:300 and N Engl J Med 1995;333:595–6]. N Engl J Med 1992; 326: 1456–1463
   PubMed Web of Science ®Google Scholar
• Ricketts R R, Hatley R M, Corden B J, et al. Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg 1994; 219: 605–614
   PubMedGoogle Scholar
• Chang E, Boyd A, Nelson C C, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. Journal of Pediatric Hematolology and Oncology 1997; 19: 237–244
   PubMed Web of Science ®Google Scholar
• Bauman N M, Burke D K, Smith R J. Treatment of massive or life-threatening hemangiomas with recombinant alpha (2a)-interferon. Otolaryngol Head Neck Surg 1997; 117: 99–110
   PubMedGoogle Scholar
• Greinwald J H, Jr, Burke D K, Bonthius D J, et al. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg 1999; 125: 21–27
   PubMedGoogle Scholar
• Barlow C F, Priebe C J, Mulliken J B, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998; 132: 527–530
   PubMed Web of Science ®Google Scholar
• Michaud A, Bauman N M, Burke D K, et al. Spastic diplegia and other motor disturbances in infants receiving interferon alfa. Laryngoscope 2004; 114: 1231–1236
   PubMed Web of Science ®Google Scholar
• Ghadially F N. Ultrastructural Pathology on the Cell and Matrix. Crystalline Inclusions. Butterworth, London 1988; 978
   Google Scholar
• Adams D, Orme L, Bowers D. Vincristine treatment for complicated hemangiomas. Abstract presented at 14th International Workshop on Vascular Anomalies, NijmegenNetherlands, June, 282002
   Google Scholar
• Boehm D K, Kobrinsky N L. Treatment of cavernous hemangioma with vincristine. Ann Pharmacother 1993; 27: 981
   PubMedGoogle Scholar
• Moore J, Lee M, Garzon M, Soffer S, Kim E, Saouaf R, et al. Effective therapy of a vascular tumor of infancy with vincristine. J Pediatr Surg 2001; 36: 1273–1276
   PubMedGoogle Scholar
• Payarols J P, Masferrer J P, Bellvert C G. Treatment of life-threatening infantile hemangiomas with vincristine. N Engl J Med 1995; 333: 369
   PubMedGoogle Scholar
• Thomson K, Pinnock R, Teague L, et al. Vincristine for the treatment of Kasabach-Merritt syndrome: recent New Zealand case experience. The New Zealand Medical Journal 2007; 120(1249)1–10
   Google Scholar
• Rush B F. Treatment of a giant cutaneous hemangioma by intraarterial injection of nitrogen mustard. Ann Surg 1966; 164: 921–923
   PubMedGoogle Scholar
• al-Rashid R A. Cyclophosphamide and radiation therapy in the treatment of hemangioendothelioma with disseminated intravascular clotting. Cancer 1971; 27: 364–368
   PubMedGoogle Scholar
• Alkalay A L, Puri A R, Pomerance J J, et al. Mesenchymal hamartoma of the liver responsive to cyclophosphamide therapy: therapeutic approach. J Pediatr Surg 1985; 20: 125–128
   PubMedGoogle Scholar
• Castro R, Meek R, Bean C, et al. Successful treatment of a giant cavernous hemangioma with oral cyclophosphamide (Cytoxan) in an infant. Del Med J 1992; 64: 745–749
   PubMedGoogle Scholar
• Hurvitz S A, Hurvitz C H, Sloninsky L, Sanford M C. Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol 2000; 22: 527–532
   PubMed Web of Science ®Google Scholar
• Gottschling S, Schneider G, Meyer S, et al. Two infants with life-threatening diffuse hemangiomatosis treated with cyclophosphamide. Pediatr Blood Cancer 2006; 46: 239–242
   PubMedGoogle Scholar
• Wilson M W, Hoehn M E, Haik B G, et al. Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangioma of the orbit. Ophthalmology 2007; 114: 1007–1011
   PubMedGoogle Scholar
• Beutner K R, Spruance S L, Hougham A J, Fox T L, Owens M L, Douglas J M, Jr. Treatment of genital warts with an immune response modifier (imiquimod). J Am Acad Dermatol 1998; 38: 230–239
   PubMed Web of Science ®Google Scholar
• Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807–813
   PubMed Web of Science ®Google Scholar
• Hengee U R, Stark R. Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 2001; 137: 709–711
   PubMedGoogle Scholar
• Stockfleth E, Meyer T, Benninghoff B, Christofers E. Successful treatment of actinic keratosis with imiquimod cream 5%: A report of six cases. Br J Dermatol 2001; 144: 1050–1053
   PubMed Web of Science ®Google Scholar
• Murchinson A P, Washington C V, Soloman A R, et al. Ocular effects of imiquimod with treatment of eyelid melanoma in situ. Dermatologic Surgery 2007; 33: 1136–1138
   PubMedGoogle Scholar
• Leppala J, Kaarniranta K, Uusitalo H, et al. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand Aug, 2007; 85(5)566–568
   PubMedGoogle Scholar
• Sauder D N. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43: S6–S11
   PubMed Web of Science ®Google Scholar
• Martinez M I, Sanchez-Carpintero I S, North P E, et al. Infantile hemangioma: Clinical resolution with 5% imiquimod cream. Archives of Dermatology 2002; 183(7)881–884
   Google Scholar
• Ho N T, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: A retrospective study. J Am Acad Dermatol Jan, 2007; 56(1)63–68
   PubMed Web of Science ®Google Scholar
• Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med Jun 12, 2008; 358(24)2649–2651
   PubMed Web of Science ®Google Scholar
• D'Angelo G, Lee H, Weiner R I. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997; 67: 353–366
   PubMed Web of Science ®Google Scholar
• Sommers Smith S K, Smith D M. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002; 38: 298–304
   PubMed Web of Science ®Google Scholar